Yifeng Yuan

Public M&A

• Represented Novo Holdings in its $16.5 billion all-cash acquisition of Catalent, Inc. (CTLT)
• Represented Blueprint Medicines Corporation (BPMC) in its acquisition by Sanofi for $9.5 billion including contingent value rights
• Represented SailPoint Technologies (SAIL) in its $6.9 billion sale to Thoma Bravo 
• Represented Zuora, Inc. (ZUO) in its $1.7 billion sale to Silver Lake and GIC
• Represented iRobot Corporation (IRBT) in its $1.4 billion sale to Amazon
• Represented Berkshire Grey (BGRY) in its rule 13e-3 sale to the SoftBank Group, valued at approximately $375 million
• Represented eMagin Corporation (EMAN) in its acquisition by Samsung Display Co. in an all-cash transaction valued at approximately $218 million
• Represented Akili Interactive (AKLI) in its acquisition through tender offer by Virtual Therapeutics
• Advised Qatalyst Partners in its role as exclusive financial advisor to Alteryx, Inc. (AYX)’s acquisition by Clearlake Capital Group, L.P. and Insight Partners in a transaction valued at $4.4 billion
• Represented Gelesis Holdings (GLS) in its rule 13e-3 sale to PureTech

Private M&A

• Represented Tubulis GmbH in its acquisition by Gilead Sciences, Inc. (GILD) for $3.15 billion in upfront cash consideration, with up to an additional $1.85 billion in contingent milestone payments
• Represented Arthrosi Therapeutics, Inc. in its sale to Sobi for up to $1.5 billion, consisting of an upfront consideration of $950 million, together with up to $550 million in milestone payments
• Represented Cybereason, a SoftBank-backed Leading Endpoint Detection and Response (ERD) company, in its proposed acquisition of Trustwave, a cybersecurity and managed security services company
• Represented Axon Communications, Inc., a digital marketing agency, in its sale to Relevate Health, an omnichannel marketing agency
• Represented Kambr, Inc., a revenue management system for airlines, in its sale to Amadeus
• Represented A&M Capital Opportunities’ portfolio company in its acquisition of 12 car wash entities and three add-on acquisitions

Reverser Merger/De-SPAC

• Represented Ikena Oncology, Inc. (IKNA) in its merger with Inmagene Biopharmaceuticals 
• Represented Aerovate Therapeutics, Inc. in its merger with Jade Biosciences, Inc.
• Representing Freenome Holding, Inc. in its business combination with Perceptive Capital Solutions Corp. (PCSC) with a post-transaction equity value of approximately $1.1 billion at closing
• Represented TheRas, Inc. (d/b/a BridgeBio Oncology Therapeutics) in its business combination with Helix Acquisition Corp. II
• Represented Arrowroot Acquisition Corp. (ARRW) on its acquisition of iLearningEngines, Inc., an AI-powered intelligence platform
• Represented Forge Global, Inc. in its business combination with Motive Capital Corp. (MOTV)
• Represented Circle Internet Financial, Inc. in its proposed $9 billion de-SPAC transaction with Concord Acquisition Corp. (CND)

Capital Market Transactions

• Advised underwriting syndicate on Lineage (LINE)’s $5.1 billion initial public offering, the largest REIT IPO in history
• Represented Ocugen, Inc. (OCGN) in its $16.5 million public offering of common stock in a bought offering deal
• Represented TransCode Therapeutics Inc. (RNAZ) in its $7 million public offering
• Represented Canaccord Genuity Group Inc. in Blue Apron (APRN)’s ATM offerings

Company Side

• Engineer.ai Corporation in its Series D financing
• Avenge Bio, Inc. in its Series A financing
• Altan Insights, LLC in its Series Seed financing
• Sentinel BioTherapeutics in its Series Seed financing

Investor Side

• Valar Ventures in its Series A financing of Link Financial
• Left Lane Capital in its Series A financing of Lemonade
• Left Lane Capital in its Series A financing of Perry Health
• Level Equity Management, LLC in its Series A financing of SchoolPass, Inc.
• Greycroft and Acrew in their Series Seed financing of NextData
• LDV Capital in its Series Pre-Seed financing of Burner Page, Inc.